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Introduction
In the 1992 National Institutes of Health (NIH)
Consensus Development Conference, impotence was
deﬁned as ‘inability of the male to attain and main-
tain erection of the penis sufﬁcient to permit satis-
factory sexual intercourse’ (1). There are two
relevant aspects of this deﬁnition. First, ‘satisfactory
sexual intercourse’ usually includes participation of a
partner, thus rendering the problem a couple-based
condition (2). Second, NIH panellists included the
patient-related outcome of satisfaction in the deﬁni-
tion of erectile dysfunction (ED) as a clinical entity.
Satisfactory ED treatment outcomes are subjective,
span psychosocial and medical domains, and are
hence determined chieﬂy by the patient and his part-
ner in consultation with a physician.
For many patients and their sexual partners, ED
reduces quality of life (QOL) and causes emotional
distress (3–9). However, despite an emerging can-
dour about ED and widespread educational activities
supporting phosphodiesterase type 5 (PDE5) inhibi-
tors since approval of sildenaﬁl citrate in many mar-
kets (in 1998), these medications (and ED in
general) continue to be misunderstood and⁄or inef-
fectively used. As a result, there are perhaps millions
of men experiencing the ‘insult’ of ineffective PDE5
inhibitor treatment added to the ‘injury’ of ED. Up
to 52% of US middle-aged and older men have ED
(10–12); however, many do not seek medical atten-
tion (13), do not receive prescription treatment [84–
93% (10,13)] or discontinue treatment (10,13–15).
In fact, one in three men discontinue ‘successful’
treatment with a PDE5 inhibitor [i.e. treatment that
restores erectile function (EF)], sometimes after the
ﬁrst prescription (16,17). In one study, 54 (35%) of
156 patients with successful restoration of normal
EF using sildenaﬁl discontinued treatment after
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not being emotionally ready to resume sexuality after
a long abstinence (37%); concerns about medication
adverse effects (18%); return of spontaneous
erections (15%); unwillingness to accept a ‘drug-
dependent erection’ (7%) and either the unaccept-
ability of planned sexual activity or lack of sexual
interest (4% each) (17).
In light of these considerable challenges, the aim
of this review was to examine practical strategies that
primary-care physicians and others can adopt to help
optimise treatment outcomes once a patient or cou-
ple has decided to receive therapy with a PDE5
inhibitor; and increase overall ‘therapeutic yield’, or
the numbers of patients experiencing optimal out-
comes.
Methods
Data sources and extraction
A PubMed search of the English-language literature
was conducted covering the period of 1 January 1998
[the year that the PDE5 inhibitor sildenaﬁl citrate
(Viagra
 ; Pﬁzer, New York, NY, USA) was approved
for use in many markets], through 31 August 2008.
Our search used the following terms: (i) title
words ‘phosphodiesterase’, ‘PDE5’, ‘sildenaﬁl’, ‘tad-
alaﬁl’ (Cialis
 ; Eli Lilly, Indianapolis, IN, USA) and
‘vardenaﬁl’ [vardenaﬁl hydrochloride (Levitra
 );
Bayer, Wayne, NJ, USA], each separated by the Bool-
ean operator ‘OR’; (ii) NIH National Library of
Medicine medical subject headings (MeSH terms)
‘human’, ‘impotence’ and ‘treatment outcome’ (each
separated by OR); (iii) title terms ‘adher*’, ‘choice*’,
‘compl*’, ‘couple*’, ‘discont*’, ‘effect*’, ‘efﬁc*’, ‘fail*’,
‘optim*’, ‘partner*’, ‘prefer*’, ‘quality’, ‘respon*’,
‘satisf*’, ‘sexual*’ and ‘succe*’ (each separated by
OR); (iv) the Boolean operator ‘NOT’ and publica-
tion types ‘letter’, ‘editorial’ or ‘review’ and (v) the
operator NOT and ‘benign’, ‘BPH’, ‘pulmonary’,
‘PAH’, ‘PPH’ and ‘PH’ (abbreviations refer to benign
prostatic hyperplasia, pulmonary arterial hyperten-
sion, primary pulmonary hypertension and pulmo-
nary hypertension, respectively) because these latter
terms refer to potential non-ED indications. The
search produced 182 citations, 93 of which were
included. Pilot studies were excluded, as were trials
conducted outside North America, consistent with
the English-language reference search and to limit
the scope of the review. Also excluded were studies
involving second-line PDE5 inhibitors, diagnostics
and other special clinical settings, and investigations
involving unapproved medications or off-label uses
of medications. To complement this search and to
help survey other associated therapies in patients
with suboptimal responses to PDE5 inhibitors, a sec-
ond search was conducted, which substituted the fol-
lowing title terms in (iii) above: ‘androg*’, ‘cardio*’,
‘coron*’, ‘counsel*’, ‘horm*’, ‘life*’, ‘mood’, ‘obes*’,
‘overweight’, ‘prost*’ and ‘testos*’. This search pro-
duced 12 additional citations, 10 of which were
included; the other two involved a pilot study and a
clinical trial concerning second-line sildenaﬁl use
after intracavernosal injection therapy (ICIT).
These literature searches were supplemented by
reviewing manufacturer labelling for each PDE5
inhibitor (18–20) and by including other relevant
articles, including consensus treatment guidelines, as
well as by reviewing article bibliographies.
Results
According to our data review, physician activities to
help maximise the likelihood of satisfactory treatment
outcomes and promote medication adherence with
PDE5 inhibitors can be subsumed under the mne-
monic ‘EPOCH’: E = evaluate⁄educate⁄expectations,
P = prescribe, O = optimise⁄titrate, C = control
comorbidities⁄counsel, H = help the patient and his
partner identify (non-PDE5-based) satisfactory ther-
apy (Figure 1).
Evaluate⁄educate⁄expectations
Evaluate
Consensus guidelines recommend, at minimum, a
medical, sexual and psychosocial history; and a
focused physical examination and laboratory tests
(Figure 2A; 21,22). A complete medical history places
the diagnosis of ED in the appropriate medical con-
text for each patient. A physical examination of the
genitourinary system can identify anatomic causes of
ED, which might warrant referral to a urologist
(23,24). A more comprehensive workup, including
recommendations for referrals, is shown in Fig-
ure 2(B) (22). The clinician can also use the Interna-
tional Index of Erectile Function (25) or the Sexual
Health Inventory for Men (SHIM) (26), which
involves (i) erection conﬁdence, (ii) erection ﬁrm-
ness, (iii) frequency of maintaining erection, (iv) fre-
quency of maintaining erection to completion of
intercourse and (v) intercourse satisfaction.
Erectile dysfunction may be viewed as a ‘portal to
men’s health’ (27). A diagnostic workup for comor-
bidities may assist not only in optimising treatment
but also in identifying other conditions, including
depressive disorders, male hypogonadism and the
presence of other cardiovascular risk factors. Endo-
thelial dysfunction represents the ‘common denomi-
nator’ between ED and cardiovascular disease (CVD)
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increased risk of CVD (29,30).
The recommendations of the Second Princeton
Consensus Conference provide useful diagnostic and
management algorithms for patients with ED and
CVD (31–33). Most men with such conditions who
are not taking nitrates may be treated with PDE5
inhibitors. Obtaining a complete medical history is
also important to uncover potentially modiﬁable iat-
rogenic causes of ED (Table 1; 34).
Educate
Counselling patients about ED treatments need not
be time consuming and can enhance treatment.
Recent studies found that weekly group counselling
sessions plus sildenaﬁl treatment were associated with
superior responses on the SHIM compared with
sildenaﬁl alone or counselling alone (35–37). In a
study involving primary-care physicians spending
about 12 min per patient, approximately 42% of
patients who had failed to respond to sildenaﬁl and
were eligible for analysis achieved salvage after being
re-educated (38). Salvage, deﬁned by positive
responses to the global assessment questionnaire after
initially not showing such responses, has also been
achieved in patients using daily tadalaﬁl after sub-
optimal responses to on-demand therapy (39). At
minimum, a few central educational messages con-
cerning PDE5 inhibitors should be communicated
(Table 2; 40–45).
Pharmacokinetic differences among the three
PDE5 inhibitors may enable the physician to individ-
ualise treatment. Tadalaﬁl has a longer half-life
(17.5 h) than sildenaﬁl (4–5 h) or vardenaﬁl (4–5 h),
promoting erectile responses to arousal for up to
36 h after dosing (46). The half-life of sildenaﬁl pro-
motes erectile responses to arousal for up to 12 h
(47), whereas the half-life of vardenaﬁl does so for
up to 8 h (48). Certain couples may appreciate hav-
ing more ‘spontaneous’, ‘relaxed’ or ‘natural’ sex
with less planning around dosing. Studies have dem-
onstrated patient and⁄or partner preferences for and
higher satisfaction with tadalaﬁl compared with other
PDE5 inhibitors, but many of these studies had
design limitations (49–59). On the other hand, many
couples preferring sildenaﬁl may value the fact that it
has the longest postmarketing surveillance record
(10 years), while those preferring either sildenaﬁl or
vardenaﬁl may value the more rapid reversibility of
these agents’ pharmacodynamic effects.
Despite certain differences in PDE5 inhibitors,
clinical trials suggest that monotherapy with either
sildenaﬁl, tadalaﬁl or vardenaﬁl restores erectile
responses to sexual arousal in most patients, includ-
ing those seen in different treatment settings, those of
different ages and ethnicities, and⁄or those with ED
of varying severities, aetiologies, comorbidities and
other conditions (46,60–81). Such treatment may also
improve sexual satisfaction, self-esteem, QOL, depres-
sive symptoms, communication and other psycho-
social outcomes for patients and⁄or their partners
(3,49–56,60–64,82–84). All three agents potentiate
erectile response and permit successful intercourse in
most men within 30–60 min after dosing on an
empty stomach (46,65–68). Data have shown that the
duration of erection sufﬁcient for successful sexual
intercourse was more than double (12.8 ± 1.00 min)
in men taking vardenaﬁl 10 mg 60 min before inter-
course compared with that of counterparts receiving
placebo (5.4 ± 1.00 min; p < 0.001) (85,86).
Figure 1 Physician activities to optimise treatment of erectile dysfunction with phosphodiesterase type 5 (PDE5) inhibitors
can be readily remembered by the mnemonic ‘EPOCH’. ICIT, intracorporeal (intracavernosal) injection therapy; VED,
vacuum erection device
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Journal compilation ª 2009 Blackwell Publishing Ltd Int J Clin Pract, August 2009, 63, 8, 1214–1230Figure 2 Evaluation of the patient with erectile dysfunction (ED) by consensus guidelines. Panel (A) Minimal diagnostic
evaluation (basic workup) according to the European Association of Urology (21). Panel (B) Complete diagnostic
algorithm for ED according to the World Health Organization and other health authorities (22), including guidelines for
referrals of patients to specialists. CV, cardiovascular; IIEF, International Index of Erectile Function. Reproduced with
permission from Wespes et al. (21) and Lue et al. (22). Panel A reprinted from EAU guidelines on erectile dysfunction: an
update. Vol 49, Wespes E, Amar E, Hatzichristou D et al., 806–815, 2006, with permission from Elsevier. Panel B
reproduced with permission of Blackwell Publishing Ltd., Summary of the recommendations on sexual dysfunctions in
men, Lue TF, Giuliano F, Montorsi F et al. 2004
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Researchers have conducted analyses to determine
factors inﬂuencing QOL, mood and sexual satisfac-
tion in patients and their partners (87). Deﬁning sat-
isfaction relates to the degree to which treatment
outcomes are compatible with expectations and it is
considered instrumental in maintaining long-term
treatment adherence with PDE5 inhibitors (40). To
help promote treatment satisfaction, it is useful to
identify any false expectations about sexual function
and the effects of PDE5 inhibitors. Patients and part-
ners should not expect successful intercourse on the
ﬁrst attempt after the ﬁrst use of a PDE5 inhibitor
(Figure 3; 43) [Each PDE5 inhibitor should be taken
‡ 4 times before it is deemed ineffective (Table 2;
21)]. Althof and Wieder (45) have identiﬁed some
other key myths to debunk (Table 2). Treatment
with PDE5 inhibitors also does not ensure more sat-
isfying sex or a more satisfying relationship.
Special case for evaluation, education and
expectations: importance of the sexual partner
Patients and partners may have different needs,
expectations or priorities for ED treatment, which
may vary depending on religion, culture, patient age
and other factors (88). It has been written that
‘when…sexual inadequacy is present, the couple is
the patient’ (89). The interdependence of sexual
Table 1 Evaluation: potential iatrogenic causes of sexual dysfunction, including erectile dysfunction
Cause Effect Probable mechanism
Medication
Antidepressants ED, ﬂsexual desire, retarded ejaculation Descending inhibitory input to sacral serotonergic
‘sex center’ + peripheral anticholinergic effects;
potentially reversed by cyproheptadine (serotonin
antagonist) or bethanechol (cholinergic)
Antihypertensives (e.g. a-methyldopa, reserpine) ﬂSexual desire, ED, retarded ejaculation Deplete central dopamine, which mediates neural
input related to sexuality (in hypothalamus⁄
paraventricular nucleus); lower blood pressure;
direct actions in corpus cavernosum (e.g.
intracellular calcium regulation); effects on
neurotransmitters⁄hormones (e.g. ›prolactin)
Other cardiovascular agents (e.g. digoxin,
disopyramide, antihyperlipidemics, propranolol)
ED, ﬂsexual desire Digoxin ﬂtestosterone and ›oestrogen levels
because of similar structure to sex steroids;
digoxin also blocks Na-K-ATPase pump with net
increase in intracellular calcium and increased
corporeal smooth-muscle tone (anti-erectile
effects)
Diuretics ED (thiazide), ﬂsexual desire, gynaecomastia
and⁄or mastodynia (spironolactone,
bendroﬂuazide, HCTZ)
Spironolactone blocks testosterone synthesis and
competitively binds to androgen receptors
Antipsychotics (neuroleptics) ﬂSexual desire, ED, retarded ejaculation (with or
without priapism)
Block pituitary⁄hypothalamic dopamine receptors;
›prolactin levels; anticholinergic activity +
a-adrenergic activity; indirect effects secondary to
weight gain, CNS sedation, parkinsonism,
psychomotor retardation
Drugs of abuse (e.g. cocaine, amphetamines) ED Diffuse atherosclerotic changes⁄endothelial
toxicity + ›a-adrenergic activity on chronic use
Histamine (H2) blockers ﬂSexual desire (cimetidine), ED, gynaecomastia Anti-androgen activities⁄blockade of androgen
receptors; ›prolactin; direct corporeal effects
Anti-androgens (e.g. ﬁnasteride) ED, reduced sexual desire Block androgen synthesis; oestrogen, ketoconazole
and digoxin may lower serum testosterone and⁄or
competitively bind to androgen receptors
Surgery⁄radiation⁄brachytherapy (e.g. for
prostate cancer)
ED Effects on neurovascular structures
Adapted from Rehman and Melman (34) with permission. ED, erectile dysfunction; HCTZ, hydrochlorothiazide; CNS, central nervous system. Adapted from (CMG and
Atlas of Clinical Urology: Impotence and Infertility. Vol 1. Philadelphia, PA: Current Medicine Inc; 1999:1.1–1.16, Figure 1–17, page 1.14, Rehman J, Melman A.
Pathophysiology of erectile dysfunction.) with kind permission of Current Medicine Group, LLC. ª 1999 All rights reserved
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partners has been demonstrated by Heiman et al.
(84), among other investigators. The overall health,
sexual and emotional status of the female partner
can exacerbate sexual dysfunction in the ED patient.
In one survey of female partners of men with ED,
82% rated sexual activity as an important aspect of
life, 76% reported being sexually active and 40%
reported engaging in vaginal intercourse, yet 34%
reported sexual dissatisfaction, 30% arousal⁄lubrica-
tion difﬁculty, 26% anxiety⁄inhibition, 24% orgasmic
difﬁculty, 18% dyspareunia and 8% incontinence
during intercourse. A total of 44% had depressive
symptoms (90).
In the Female Experience of Men’s Attitudes to
Life Events and Sexuality (FEMALES) study, partners
of men with ED reported signiﬁcant deﬁcits in sexual
desire, arousal, orgasm and overall sexual satisfac-
tion, with the degree being signiﬁcantly correlated
with ED severity (91). Conversely, PDE5 inhibitor
therapy in the male patient was associated with
improved sexual experiences in the partner, and was
particularly effective in men with severe ED and a
supportive female partner (91). Similar ﬁndings have
been reported in trials involving each of the PDE5
inhibitors (54,63,92).
Although the partner should be involved in ED
assessment and treatment planning as early as possi-
ble (22), consensus guidelines have stated that no
patient with ED should be denied treatment solely
on the basis of his partner’s being unwilling or
unable to accompany him to the initial ED ofﬁce
visit (93). Whether the partner decides to accompany
the patient is largely informed by sociocultural fac-
tors and individual preferences and needs (22).
When the partner is not available, it is still important
to ask about her sexual health and satisfaction, and
it may ultimately be necessary to address her sexual
problems to optimise ED treatment outcomes
(30,89). According to Althof, ‘before concluding that
treatment has failed, the clinician must consider the
myriad biopsychosocial reasons that could…prevent
the couple from attaining their stated goal’ (94).
Such ‘biopsychosocial obstacles’ include a long per-
iod of sexual abstinence before treatment, a subopti-
mal non-sexual relationship and⁄or the female
partner not being emotionally and⁄or physically pre-
pared to resume lovemaking (94). Other potential
issues in the female partner include an overall
aversion to sex, sexual pain (e.g. vaginismus,
dyspareunia) and low desire⁄arousal (30). It is
often useful to invite the patient and partner to
Table 2 Education and expectations: key educational messages, common myths and cognitive distortions in men with
erectile dysfunction
Key educational messages
PDE5 inhibitors are not ‘erectogenic’ agents per se. They are considered ‘contingent agonists’ of the sexual response and are hence
effective only in the presence of sexual arousal⁄stimulation
Sufﬁcient arousal and sexual stimulation are particularly important in elderly men, including those with diabetes, who may have
increased sensory (tactile) thresholds (41,42)
PDE5 inhibitors are not always successful in restoring erectile function adequate for sexual intercourse on the ﬁrst attempt. Each
PDE5 inhibitor should be taken ‡ 4 times before it is deemed ineffective
Myths
It is the responsibility of the man to satisfy the woman
Size and ﬁrmness of the erect penis are necessary determinants of the female partner’s satisfaction
A woman’s favourite part of sex is intercourse
A man always wants and is always ready to have sex
With age, all men lose their ability to achieve erections
Cognitive distortions
All-or-nothing thinking, e.g. ‘I am a complete failure because my erection was not 100% rigid’
Overgeneralisation, e.g. ‘If I had trouble getting an erection last night, I won’t have one this morning’
Disqualifying the positive, e.g. ‘My partner says I have a good erection because she doesn’t want to hurt my feelings’
Mind reading, e.g. ‘I don’t need to ask. I know how she felt about last night’
Fortune telling, e.g. ‘I am sure things will go badly tonight’
Emotional reasoning, e.g. ‘Because a man feels something is true, it must be’
Categorical imperatives, e.g. ‘should’, ‘ought to’ and ‘must’ dominate the man’s cognitive processes
Catastrophising, e.g. ‘If I fail to achieve an erection tonight, my partner will abandon me’
Adapted with permission from Althof and Wieder (45). Adapted with kind permission from Springer Science+Business Media: Endo-
crine, Psychotherapy for erectile dysfunction: now more relevant than ever. Vol 23, 2004, page 132, Althof SE, Wieder M, Section IV.
Permission also obtained from Althof SE
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failure, to better appreciate the sources of problems.
Successful ED treatment should accommodate the
behavioural complexity of sexual intimacy, including
patient–partner communication. Predisposing, pre-
cipitating and maintaining factors, as well as the
presence and quality of morning erections and part-
ner issues related to sexual aversion, menopause, vag-
inal atrophy⁄pain or dyspareunia, should be assessed
(Table 3; 30). Women need to be physically and
emotionally ready to resume or increase their
amount of lovemaking with the patient. For example,
treatment recommendations (including the use of
local oestradiol) have been developed for sexual pain
associated with vaginal atrophy, which is very com-
mon in women > 50 years of age (30,92,95,96) and
may also result from diabetes or as a side effect of
certain medications.
Female sexuality is complex; research concerning
the pathophysiology of, and potential pharmacother-
apy for, female sexual dysfunction lags signiﬁcantly
behind that concerning male sexual dysfunction
(97,98). In this context, it has been asserted that
‘despite recognising the importance of women’s
sexual health, few healthcare providers have the
knowledge to treat women, or men and women
together as a couple’ (98).
These limitations aside, female partners with sexual
dysfunction should be treated where possible, pro-
vided with sound education or referred to specialists
as appropriate. According to recent consensus guide-
lines, ‘As sex is a subjective experience…all couples
affected by sexual dysfunction have…some psycho-
logical component to their problem. Almost all…will
beneﬁt from simple sex education’ (30). This includes
‘behavioural advice regarding foreplay, sexual activity
Figure 3 Cumulative proportion of men taking tadalaﬁl able to achieve (A) their ﬁrst successful penetration [Sexual
Encounter Proﬁle Question (SEPQ) 2], (B) ﬁrst successful intercourse (SEPQ3) and (C) to experience sexual satisfaction
(SEPQ5) by dose. Reprinted from Schulman et al. (43). Reprinted from Urology, 64, Schulman CC, Shen W, Stothard DR,
Schmitt H, Integrated analysis examining ﬁrst-dose success, success by dose, and maintenance of success among men
taking tadalaﬁl for erectile dysfunction, 783–8, 2004, with permission from Elsevier.
Table 3 Causes of erectile dysfunction
Predisposing Precipitating Maintaining
Lack of sexual knowledge New relationship Relationship problems
Poor past sexual experience Acute relationship problems Poor communication between partners
Relationship problems Family⁄social pressures Lack of knowledge about treatment options
Religious⁄cultural beliefs Pregnancy⁄childbirth Ongoing physical or mental health problems
Restrictive upbringing Other major life events Other sexual problems in the man or his partner
Unclear sex⁄gender preference Partner’s menopause Drugs (see also Table 1)
Previous sexual abuse Acute physical or mental health problems
Physical⁄mental health problems Lack of knowledge about normal changes of ageing
Other sexual problems in the man or his partner Other sexual problems in the man or his partner
Drugs (see also Table 1) Drugs (see also Table 1)
Adapted with permission from Hackett et al. (30). Adapted with permission of Blackwell Publishing Ltd., Hackett G. Kell P, Ralph D et al, British Society for Sexual
Medicine guidelines on the management of erectile dysfunction. J Sex Med 2008; 5: 1841–65.
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sexual behaviour’ (30). When the psychosocial history
or other discussions with the patient and partner
identify psychological and relationship issues, couples
may beneﬁt from psychosexual or couples therapy.
Sex therapists can help to instruct patients and
partners in sexual enhancement techniques and also
to address relationship problems. In many cases,
sexual problems represent manifestations of broader
communication and relationship issues, including
mistrust, anger and power struggles (99). Formal
cognitive-behavioural interventions by professional
therapists may also beneﬁt some couples (30).
Referrals to sex therapists can be arranged through
the American Association of Sexuality Educators
Counselors and Therapists (Ashland, VA; http://www.
aasect.org; 804-752-0026) and to marital therapists
through the American Association for Marriage and
Family Therapy (Alexandria, VA; http://www.aamft.
org or http://www.therapistlocator.net/; 703-838-9808).
In summary, the primary-care physician is ideally
poised to help patients with ED and their partners
by assessing the problem; providing sound education,
including a focus on pleasure and arousal (via more
prolonged foreplay and sensuality) rather than erec-
tion; and⁄or referring couples to a sex therapist, psy-
chotherapist or marriage counsellor, as needed (99).
Finally, medical therapy and counselling couples or
psychosexual therapy are not mutually exclusive;
recent evidence suggests that a combination of such
therapies can enhance sexual satisfaction, intimacy
and cognition in men with ED and their female
partners (100).
Prescribe
Available regimens
Phosphodiesterase type 5 inhibitors are taken ‘on
demand’ or ‘as needed’ before sexual activity, up to
once daily. Vardenaﬁl is available in four strengths
(2.5, 5, 10 and 20 mg), allowing for dosing ﬂexibility.
Sildenaﬁl is available in three strengths (25, 50 and
100 mg). Tadalaﬁl is the only PDE5 inhibitor
approved for once-daily dosing (as 2.5- and 5-mg
tablets) and on-demand dosing (5, 10 and 20 mg).
On-demand dosing may be ideal for some couples,
whereas others may beneﬁt from a low-dose daily
dosing regimen that does not require co-ordination
of sexual activity and may particularly beneﬁt men
wishing to have sex at least twice weekly. A recent
publication suggested that efﬁcacy and tolerability
proﬁles are similar when tadalaﬁl (2.5 or 5 mg) is
administered once daily compared with as needed,
and suggested a favourable risk-beneﬁt balance for
once-daily treatment (69).
Pharmacodynamics
Phosphodiesterase type 5 inhibitors potentiate erec-
tile responses to sexual arousal by blocking the enzy-
matic degradation (by PDE5) of cyclic guanosine
monophosphate. They are highly selective for PDE5,
with an in vitro potency ratio of 41 :2 : 1 for varde-
naﬁl:tadalaﬁl:sildenaﬁl (70).
Many adverse events encountered by men taking
PDE5 inhibitors, including dyspepsia, headache, nasal
congestion and back pain, probably relate to vasodila-
tion in non-corporeal (non-penile) vascular beds. Much
less frequently, certain visual adverse events have been
reported, including non-arteritic anterior ischaemic
optic neuropathy (101–107), although their causal rela-
tionship to treatment is unclear. Sudden sensorineural
hearing loss has recently been added to the prescribing
information of all three PDE5 inhibitors (18–20).
Pharmacokinetics
All three PDE5 inhibitors are absorbed rapidly after
oral dosing, reaching maximum plasma concentra-
tions approximately 1 h after dosing for sildenaﬁl and
vardenaﬁl and 2 h after dosing for tadalaﬁl. High-fat
meal intake can inﬂuence the absorption of sildenaﬁl
and vardenaﬁl, whereas tadalaﬁl can be taken without
regard to meal intake or ‘intrinsic’ factors such as age
and diabetes mellitus (18–20,71–73). Low starting
doses are recommended for elderly men taking silde-
naﬁl or vardenaﬁl; tadalaﬁl dosage adjustment is not
necessary for otherwise healthy elderly men (18–20).
Patients are instructed to take PDE5 inhibitors
approximately 1 h before sexual activity, up to once
daily. Zinner (74) reported no signiﬁcant decline in
efﬁcacy when sildenaﬁl was taken 1 h before or during
a meal, and approximately 82% of men reported suc-
cessful intercourse > 10 h after sildenaﬁl dosing.
All three PDE5 inhibitors are distributed widely
throughout tissues and are extensively (‡ 94%) pro-
tein bound, with foecal excretion as the main route
of elimination. They are also substrates for oxidative
metabolism by cytochrome P450 3A4⁄5 (CYP3A4⁄5)
isoenzymes. Drug-drug interactions that can compro-
mise efﬁcacy include concomitant PDE5 inhibitors
and CYP3A4⁄5 inducers, such as rifampin. Interac-
tions that can compromise tolerability include con-
comitant PDE5 inhibitors and CYP3A4⁄5 inhibitors.
Reduced doses of PDE5 inhibitors are recommended
when they are co-administered with certain human
immunodeﬁciency virus protease inhibitors as well as
other CYP inhibitors.
Optimise⁄titrate
Follow-up visits are important for optimising patient
and partner responses to ED treatment. The ﬁrst step
is to educate men concerning the salient pharmaco-
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affect usage patterns and treatment outcomes. With
sildenaﬁl, this has often involved educating patients
about the availability of the 100-mg dose to optimise
erectile hardness and other intermediate outcomes
(75–77). A study of 100 consecutive sildenaﬁl non-
responders showed that 45% of patients had never
taken the highest dose (100 mg), 32% took sildenaﬁl
after eating, 22% took the medication immediately
before initiation of sexual activity rather than 1 h
before and 12% were unaware that sexual stimula-
tion was necessary to achieve an erection (78). Only
approximately one in three men reported that their
physicians had scheduled follow-up visits. After
addressing some of these issues, 31% of prior non-
responders achieved adequate responses to sildenaﬁl.
Similarly, patients taking tadalaﬁl attempted inter-
course up to 36 h after tadalaﬁl dosing when
instructed that they could do so (79–81,108). Data
from the recent, 12-month DETErminants of Con-
tinued use of Tadalaﬁl (DETECT) study suggested
that early success with tadalaﬁl was a determinant of
long-term outcomes, including medication adherence
(Figure 4; 109).
Researchers have evaluated ﬁrst-dose successful
responses to PDE5 inhibitors as a study end-point
(110–113). In the recent Reliability of Vardenaﬁl for
Erectile Dysfunction (RELY)-II trial, 70–81% ﬁrst-
dose treatment success was reported with high-dose
(20 mg), on-demand vardenaﬁl therapy in patients
with numerous comorbidities (Figure 5; 114). Maxi-
mising ﬁrst-dose success with PDE5 inhibitors must
be balanced against the risk of suboptimal tolerability
of higher doses.
In a prospective, open-label, ﬂexible-dose study
involving sildenaﬁl, Steidle et al. (75) identiﬁed
patient comments as to dissatisfaction with sildenaﬁl
treatment, as well as steps that physicians can take to
enhance treatment outcomes (Table 4).
Control comorbidities⁄counsel
To our knowledge, limited high-quality, randomised,
controlled trials have compared PDE5 inhibitor
treatment outcomes in patients with or without ade-
quate control of comorbidities, including serum lip-
ids, haemoglobin A1c, blood pressure, endocrine
levels⁄function and⁄or psychiatric difﬁculties. How-
ever, these conditions can compromise EF and war-
rant consideration, particularly when initial
responses to PDE5 inhibitors are suboptimal.
Male hypogonadism
There is a substantial frequency of comorbid hypo-
gonadism with ED, and the conditions also often
coexist with major depressive disorder, cardiovascu-
lar disease, diabetes and⁄or metabolic syndrome;
however, male endocrine decline is not inevitable
(115–119). Age-related declines in reproductive hor-
mone output in men may be accompanied by sexual
dysfunction, as well as reduced lean muscle mass,
bone density and sense of well-being.
Because hypogonadism can attenuate male sexual
desire, some patients with suboptimal responses to
PDE5 inhibitors may beneﬁt from adjunctive exoge-
nous testosterone treatment. Adjunctive transdermal
testosterone and oral testosterone undecanoate
have been evaluated in combination with sildenaﬁl
(120–126). In randomised, double-blind, placebo-
controlled trials, T-gel enhanced sexual function,
including nocturnal erections, circulating testosterone
level and intercourse frequency, in hypogonadal men
with initially suboptimal responses to sildenaﬁl
Figure 4 Severity of erectile dysfunction by the International Index of Erectile Function (Erectile Function domain) at
baseline and tadalaﬁl treatment months 1, 6 and 12 among men continuing to take tadalaﬁl (10–20 mg) at 12 months
(n = 1319). Reproduced from Roumegue `re et al. (109). Reproduced with permission of Blackwell Publishing Ltd.,
Roumegue `re T, Verheyden B, Arver S et al. Therapeutic response after ﬁrst month of tadalaﬁl treatment predicts 12
months treatment continuation in patients with erectile dysfunction: results from the DETECT study. ª 2008 International
Society for Sexual Medicine
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‘restorative’ testosterone levels and improved EF was
found in only one reported trial (126).
Safety issues surrounding testosterone treatment
were reviewed in the New England Journal of Medi-
cine in 2004 (127,128) and, more recently, Miner
et al. developed best-practices guidelines (129). These
included obtaining a serum testosterone level when
an adult man shows symptoms or signs of hypo-
gonadism and as a component of routine screening
Table 4 Possible reasons why patients were not completely satisﬁed (and possible personalised instruction to improve efﬁcacy and satisfaction)
with sildenaﬁl
Patient comment Possible clinical response
Treatment could work faster Take the tablet on an empty stomach (i.e. either before a meal or ‡ 2 h after a meal); increase sexual stimulation
(e.g. foreplay, caressing)
Treatment could last longer If at 50-mg dose, increase the dose to 100 mg; increase sexual stimulation (e.g. foreplay, caressing); ensure that
the subject is not waiting too long after taking sildenaﬁl before attempting intercourse
Erections were not always completely hard If at 50-mg dose, increase the dose to 100 mg; increase sexual stimulation (e.g. foreplay, caressing); take on
an empty stomach; ensure that the subject is not attempting intercourse too soon after taking sildenaﬁl
Patient wanted erection to last long enough
to complete intercourse and ejaculation
If at 50-mg dose, increase the dose to 100 mg; increase sexual stimulation (e.g. foreplay, caressing); take on an
empty stomach; try having sexual activity 30 min to 1 h after taking the medication; determine if subject is
experiencing other sexual dysfunction, such as delayed ejaculation or anorgasmia, and treat accordingly
Treatment sometimes did not work perfectly If at 50-mg dose, increase the dose to 100 mg; increase sexual stimulation (e.g. foreplay, caressing); takeo na n
empty stomach; ensure that the subject is not waiting too long or trying too soon after taking the medication
to attempt intercourse
Patient wanted to have sex more than once
with the same dose of sildenaﬁl
If at 50-mg dose, increase the dose to 100 mg; increase sexual stimulation (e.g. foreplay, caressing); take on an
empty stomach; ensure that the subject is not waiting too long after taking the medication to attempt
intercourse the second time
Patient experienced side effects Remind patients that most side effects are transient, lasting a few minutes to an hour or so
Headache: take appropriate treatment before taking study medication; consider decreasing dose
Dyspepsia: take appropriate treatment before taking study medication; consider decreasing dose
Flushing: consider decreasing dose
Nasal congestion: take appropriate treatment before taking study medication; consider decreasing dose
Reproduced from Steidle et al. (75). Reprinted by permission from Macmillan Publishers Ltd: Int J of Impot Res (19) 2007.
Figure 5 First-dose success in achieving vaginal penetration (SEP2) and intercourse completion (SEP3) in men during an
open-label vardenaﬁl challenge phase. Patients included men with comorbidities, such as diabetes mellitus (DM),
dyslipidaemia (DL) or hypertension (HTN). Reproduced from Valiquette et al. (114). Reproduced from Valiquette et al.
(114) ª 2008 with permission from Canadian Urological Association
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atic men with a serum testosterone level
< 300 ng⁄ml, testosterone replacement therapy may
be considered. Effective treatment with a PDE5
inhibitor may alter the testosterone:oestradiol ratio
and play a role in moderating EF (130).
Cardiovascular lifestyle factors and counselling
Behavioural factors with potential adverse vascular
effects can also adversely affect EF. Tobacco use is
associated with vasoconstriction, endothelial toxicity,
reduced penile blood ﬂow and reduced corporeal
smooth-muscle relaxation. In a multivariate analysis,
only current smoking, hypogonadism and baseline
ED severity signiﬁcantly predicted PDE5 inhibitor
treatment failure (131).
In a study involving 110 obese men [body mass
index (BMI) ‡ 30 kg⁄m
2], those who lost ‡ 10%
total body weight had signiﬁcant improvements from
baseline in EF compared with controls. On multivari-
ate analysis, changes in BMI, body weight and the
waist:hip ratio were signiﬁcant independent factors
for improved EF (132). Moderate (13%) weight loss
in obese men and women has also been signiﬁcantly
associated with improvement in sexual QOL (133).
Erectile function may be supported by medical
management of comorbid cardiovascular conditions.
A German group recently reported the treatment of
> 1000 consecutive patients with metabolic syn-
drome using an angiotensin II receptor blocker
(ARB) with or without hydrochlorothiazide (HCTZ)
for 6 months (134). The frequency of ED declined
from 78.5% at baseline to 63.7% at treatment month
6, and men receiving an ARB with or without HCTZ
experienced signiﬁcant improvements in EF, orgas-
mic function and intercourse satisfaction. Treatment
with PDE5 inhibitors in men with hypertension,
including those receiving concomitant antihyperten-
sive medications [diuretics, b-blockers and angioten-
sin-converting enzyme (ACE) inhibitors], has been
reported to be effective and well-tolerated in manag-
ing ED (135–138).
In a small, placebo-controlled, double-blind trial,
adjunctive treatment with an ACE inhibitor (+silde-
naﬁl) signiﬁcantly augmented EF and reduced ED
symptoms compared with placebo in men with
suboptimal responses to the PDE5 inhibitor
(p < 0.01), whereas treatment with a statin also
numerically improved EF (139). In another, smaller
trial, treatment with a statin for up to 12 weeks
signiﬁcantly improved EF (increase in EF domain
score = 7.8; p = 0.04), and the clinical beneﬁts of
statins on EF were observed as early as treatment
week 6 (140). Nightly treatment with a PDE5
inhibitor has also been shown to be effective in
enhancing EF in patients with arteriogenic ED
(141); many patients with inadequate responses to
PDE5 inhibitors after prostatectomy have arterial
insufﬁciency (142,143). Certain studies have sug-
gested that enhanced control of cardiovascular risk
factors and⁄or statin treatment may increase the
efﬁcacy of PDE5 inhibitors (vs. placebo + PDE5
inhibitors) (144,145).
Prostate cancer
All three PDE5 inhibitors can improve EF in patients
after nerve-sparing radical prostatectomy and other
procedures for prostate cancer (83,146–153). Bilateral
nerve-sparing radical retropubic prostatectomy, with
preservation of neurovascular bundles, is important
for adequate responses to sildenaﬁl; other factors
associated with favourable treatment outcomes
include age £ 65 years, better preoperative EF and a
> 6-month interval after surgery, whereas androgen
deprivation therapy may adversely affect responses to
PDE5 inhibitors (148,149).
Some patients may beneﬁt from nightly treatment
with sildenaﬁl after prostate surgery (150,151). In
one study, men with nerve-sparing prostatectomy
were randomised to nightly sildenaﬁl (50 or 100 mg)
for up to 36 weeks (150). Among men randomised
to active treatment, 27% experienced spontaneous
erections compared with 4% receiving placebo
(p = 0.02). In a long-term study of 43 men with
prostate cancer who received one radioactive seed
implantation, 31 (72%) continued to have satisfac-
tory responses to sildenaﬁl at treatment year 3, with
both men and their spouses having favourable treat-
ment satisfaction (Erectile Dysfunction Inventory of
Treatment Satisfaction scores > 70) (152). Among
the 12 men who discontinued treatment, ﬁve (42%)
cited suboptimal efﬁcacy, six (50%) a return of erec-
tions adequate for vaginal penetration and one (8%)
death of spouse. Residual nocturnal penile tumes-
cence and rigidity may predict more successful PDE5
inhibitor therapy after prostate and other urological
procedures (153).
Major depressive disorder
There is a potential bidirectional relationship
between ED and depression. Treatment with certain
antidepressants may be associated with ED and
other forms of sexual dysfunction (see Table 1).
Treatment with PDE5 inhibitors can enhance sexual
function in men with ED secondary to, or in the
presence of, depression or antidepressants, including
medications affecting serotonergic pathways (154–
163). Sexual dysfunction in the setting of severe or
treatment-refractory depression warrants referral to
a specialist.
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alternative (non–PDE5-based) satisfactory
therapy
Given the subjective nature of sex and other individ-
ual relationship issues, many couples will beneﬁt
from using different treatments for ED. Recent evi-
dence suggests that patients who tried all three PDE5
inhibitors had improved outcomes, including long-
term treatment adherence (164). Other studies have
suggested that some patients will experience favour-
able responses to one PDE5 inhibitor after subopti-
mal responses to another (165).
On the other hand, no treatment (including ﬁrst-
line PDE5 inhibition) is uniformly well suited to all
patient and partner needs. Some couples will experi-
ence superior outcomes with other, second- or third-
line forms of therapy, including ICIT (166–173) or
alprostadil suppositories, sublingual apomorphine (in
non-US markets), vacuum erection⁄constriction
devices (174–176) and⁄or surgical implantation of
penile prostheses or other devices (177–181), either
alone or combined⁄alternating with PDE5 inhibitors.
In some cases, clinically occult sexual arousal disor-
ders can complicate treatment with PDE5 inhibitors,
which require sexual arousal (94). On the other
hand, the effectiveness of ICIT, vacuum erection
devices and penile prostheses are typically not
adversely affected by arousal difﬁculties in the ED
patient (94).
Potential limitations
Limitations of our analysis include the possibility of
publication bias, in which studies showing less pro-
nounced beneﬁts of PDE5 inhibitors on treatment
outcomes might not have been published, leading us
to overestimate the salutary effects of these treat-
ments. Most of the studies we evaluated involved rel-
atively short treatment intervals (< 1 year); only data
on heterosexual couples were assessed; and we did
not speciﬁcally evaluate factors affecting treatment
outcomes in patients with diabetic ED or potential
predictors of response to each PDE5 inhibitor (182–
191). We did not include agents that are investiga-
tional or approved in other parts of the world.
Finally, our mnemonic EPOCH, while evidence-
based overall, has not been validated as an effective
treatment strategy through prospective, randomised,
controlled studies or other forms of clinical
experience.
Conclusions
Erectile dysfunction is a major health issue affecting
many adult men, impairing emotional well-being,
satisfaction and overall QOL. Most men do not dis-
cuss the problem with their physicians and⁄or
receive treatment. If they do, many patients and their
partners abandon therapy. PDE5 inhibitors have
become ﬁrst-line non-invasive treatments for ED.
The literature demonstrates that successful treatment
of this condition frequently improves QOL, relation-
ship metrics and overall sexual satisfaction. In an
attempt to optimise long-term outcomes with PDE5
inhibitors, including treatment satisfaction and long-
term adherence, physicians need to educate patients
and their partners. Key elements towards optimising
ED treatments include: (i) evaluating and educating
patients and partners to ensure realistic expectations
of therapy; (ii) prescribing a treatment well suited to
the couple’s lifestyle needs and other preferences;
(iii) optimising treatment by scheduling follow-up
visits with the patient to ‘ﬁne-tune’ dosages and revi-
sit key educational messages; (iv) controlling comor-
bidities via lifestyle counselling, medications and⁄or
referrals and (v) helping patients and their partners
to address their health and psychosocial needs.
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